VAISHALI · Vaishali Pharma Ltd · Biotechnology & Drugs
VAISHALI · Vaishali Pharma Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
35.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹27 Cr
Revenue YoY
PAT YoY
+106.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.8
P/S (TTM)
1.1
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| VAISHALI (this stock) | 6.9 | 1.8 | +3.7% | +5.9% | 0.27 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 1q
FII
stable
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 03 Jul 2026 | KESAR PHARMA LIMITED | BUY | 45,37,865 | ₹3 |
| 03 Jul 2026 | KESAR PHARMA LIMITED | BUY | 45,37,865 | ₹3 |
| 03 Jul 2026 | KESAR PHARMA LIMITED | BUY | 45,37,865 | ₹3 |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedVaishali Pharma Limited's 2025-26 annual report highlights the company's focus on expanding its healthcare product portfolio and international market presence. The report emphasizes the company's commitment to operational efficiency, quality assurance, and sustainable growth through diversified product offerings and strategic supply chain management. Management discussed the importance of adaptability and innovation in navigating industry challenges and opportunities.
- Expansion of international market presence in regions like Russia, UAE, Madagascar, and Palestine
- Commitment to operational efficiency, quality assurance, and sustainable growth
- Diversified product portfolio spanning APIs, formulations, surgical products, and nutraceuticals
- Strategic supply chain and customer relationship management
Key takeaway: Vaishali Pharma Limited is focused on expanding its global footprint and maintaining operational efficiency through a diversified product portfolio and strategic supply chain management.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
Vaishali Pharma Limited was fined ₹21,24,000 (including GST) under Schedule XIX – Para (2) of the SEBI (ICDR) Regulations, 2018, and ₹15,33,600 by NSE for delay in the bonus issue due to the pendency of the warrant application with the record date of 15th October 2024.
Routine disclosures
Contingent Liability
1 occurrenceEarlier (1-3 years ago)
The company has a pending commitment to acquire 35,89,201 equity shares of Kesar Pharma Limited for ₹20.42 crores, with ₹8.17 crores in cash and ₹12.25 crores via issuance of 61,23,000 equity shares at ₹20 per share. As of March 31, 2025, the transaction remains pending execution.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company has disclosed transactions with relatives of Key Management Personnel, including payments for salary, rent, and loans, amounting to Rs. 53.11 lakhs in FY 23-24.